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ABSTRACT  27	
Osteogenesis imperfecta (OI) is a skeletal dysplasia characterized by brittle bones and 28	
extra-skeletal manifestations. The disease phenotype varies greatly. Most commonly, OI 29	
arises from monoallelic mutations in one of the two genes encoding type I collagen, 30	
COL1A1 and COL1A2 and is inherited as an autosomal dominant trait. 31	
Here we describe a consanguineous family with autosomal recessive OI caused by a novel 32	
homozygous glycine substitution in COL1A2, NM_000089.3: c.604G>A, p.(Gly202Ser), 33	
detected by whole-genome sequencing. The index patient is a 31-year-old Greek woman 34	
with severe skeletal fragility. She had mild short stature, low bone mineral density of the 35	
lumbar spine and blue sclerae. She had sustained multiple long bone and vertebral 36	
fractures since childhood and had been treated with bisphosphonates for several years. She 37	
also had an affected sister with similar clinical manifestations. Interestingly, the parents and 38	
one sister, all carriers of the COL1A2 glycine mutation, did not have manifestations of OI. 39	
In summary, we report on autosomal recessive OI caused by a homozygous glycine to 40	
serine substitution in COL1A2, leading to severe skeletal fragility. The mutation carriers 41	
lacked OI manifestations. This family further expands the complex genetic spectrum of OI 42	
and underscores the importance of genetic evaluation for correct genetic counselling. 43	
 44	
Key words: autosomal recessive; type I collagen; osteogenesis imperfecta; BMD; fracture  45	
	 3	
1. INTRODUCTION 46	
Osteogenesis imperfecta (OI) is a skeletal dysplasia characterized by bone fragility and low 47	
bone mineral density (BMD). In 9 out of 10 cases, OI is caused by dominantly inherited 48	
heterozygous mutations in one of the two genes encoding the α1 and α2 chains of type I 49	
collagen (COL1A1 and COL1A2, respectively). The remaining 10% of cases are due to 50	
autosomal recessive and X-linked mutations in one of the several other recently identified 51	
OI genes that are involved in post-translational modification of type I collagen, in osteoblast 52	
function, or in other aspects of bone metabolism [1, 2].  53	
Biallelic mutations in COL1A2 have been described in a few consanguineous families, in 54	
which OI is inherited as an autosomal recessive trait [3-5]. Depending on the location of the 55	
mutation, homozygous mutations in COL1A2 can also give rise to Ehlers-Danlos syndrome 56	
[6-8].  57	
Here we report on a novel biallelic mutation in COL1A2 causing moderately severe OI in two 58	
Greek women born to consanguineous parents.  59	
 60	
2. SUBJECTS AND METHODS 61	
2.1 Subjects 62	
As part of an ongoing research project on genetic causes of inherited skeletal diseases we 63	
recruited a Greek-Cypriot family with skeletal fragility. The index patient had traits 64	
suspicious of OI and her consanguineous parents (2nd cousins) were healthy. The patient 65	
had three sisters of whom one also had a history of multiple fractures.  66	
2.2 Methods 67	
Clinical data were collected from hospital records. In order to investigate the genetic cause 68	
of the skeletal disease in our index patient we performed whole-genome sequencing (WGS) 69	
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on all family members (index patient, her parents and her three sisters). Detailed 70	
information about this method can be found in Supplemental Appendix S1. 71	
Variant validation was performed using Sanger sequencing.  72	
 73	
3. RESULTS 74	
3.1 Clinical report 75	
A Greek-Cypriot woman, born in 1986, was first evaluated for potential OI when she was 27 76	
years old. She was born to healthy consanguineous parents (2nd cousins) at term and had 77	
no antenatal or perinatal history of note. Apart from her mild short stature, she had blue 78	
sclerae, while dentition was normal (Table 1).  79	
At age 8-11 yrs, she had suffered multiple low-energy fractures (bilateral Colle’s, forearm, 80	
clavicle, ankle, pubic bone and at least three vertebral fractures). Thereafter, she had no 81	
further skeletal complications until age 21 yrs, when she sustained a new radius fracture. 82	
After bisphosphonate treatment (oral risedronate for 1 year and thereafter 3 yearly courses 83	
of 5 mg intravenous zoledronic acid), at age 25 yrs bone mineral density (BMD) at the 84	
lumbar spine (LS) was compatible with osteoporosis (Table 1). Two years later, during a 85	
respiratory tract infection, she suffered multiple rib fractures and a comminuted right 86	
acetabular fracture after a fall from standing height (Fig. 1). She underwent internal 87	
fixation, complicated by pulmonary embolism. At that time, she received one dose (60 mg) 88	
of denosumab s.c. Three months later, at 28 yrs, she suffered a fracture of the left femoral 89	
neck. At this time some spinal changes were also detected and confirmed recently by 90	
vertebral fracture assessment (VFA) (Fig.1).  Due to this stormy clinical course, nine months 91	
later, treatment with zoledronic acid was resumed and continued until the age of 29 yrs. At 92	
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most recent evaluation at 31 yrs, she had not experienced any further fractures and BMD 93	
measurements were within normal limits (Table 1). 94	
The patient’s family history was suggestive of a recessive form of primary osteoporosis. Her 95	
parents, who were 2ndcousins, were free of skeletal fragility. The mother had osteopenia on 96	
the DXA scan but her fracture history was negative. The father’s BMD was normal. The 97	
index patient had three older sisters, two free from skeletal manifestations and one 98	
affected by excessive bone fragility and OI features, including blue sclerae and 99	
dentinogenesis imperfecta (Fig. 2A; Table 1). This affected sister had sustained a tibial 100	
fracture and multiple rib fractures between 11 and 12 yrs of age and a scaphoid fracture of 101	
the wrist at the age of 15 yrs. She also had three healthy children.  102	
3.2 Genetic investigations 103	
WGS in the six family members identified two autosomal recessive variants with potentially 104	
damaging effect: 1) a novel single nucleotide variant in exon 13 of COL1A2, NM_000089.3: 105	
c.604G>A, p.(Gly202Ser) (Fig. 2B) and 2) a 4-nucleotides intronic indel, TAAA, in RP11-106	
682N22.1, which encodes a long intergenic non-coding RNA (lincRNA). Both variants were 107	
identified in homozygosity in the index patient and her affected sister and in heterozygosity 108	
in the parents and one healthy sister. Surprisingly, all the mutation carriers were healthy. 109	
The other healthy sister was not a mutation carrier.   110	
The molecular function of the lincRNA is unknown. However, monoallelic mutations 111	
affecting the Gly-Xaa-Yaa repeats in the triple helix of type I collagen are the most common 112	
cause of OI. For this reason, we regarded the COL1A2 variant, inherited with an atypical 113	
autosomal recessive pattern of inheritance, as the cause of the disease in our index patient 114	
and her affected sister. This variant is also determined as pathogenic according to the 115	
ACMG guidelines and was confirmed by Sanger sequencing (Fig. 2C) [9].  116	
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 117	
4. DISCUSSION 118	
In this report we describe a novel autosomal recessive COL1A2 mutation, c.604G>A, 119	
p.(Gly202Ser), identified in a Greek consanguineous family. The clinical features of the 120	
index patient and her affected sister were compatible with moderately severe OI whereas 121	
the mutation carriers lacked OI manifestations. 122	
While biallelic mutations of the α1(I) chain are probably lethal, homozygous mutations of 123	
the α2(I) chain have been described in a handful of families [3-5, 10-12]. Similar to the case 124	
reported by De Paepe et al, our index patient harbours a homozygous mutation leading to 125	
glycine to serine substitution in the α2(I) chain [4]. She presents with several OI hallmarks 126	
including mild short stature, blue sclerae, low BMD and recurrent fractures since childhood. 127	
Interestingly, her fracture pattern is unusual, since it includes pelvis and acetabular 128	
fractures, which are uncommon in OI. Similarly, the affected sister had sustained multiple 129	
rib fractures and a scaphoid fracture of the wrist, both of which are not typical OI fractures. 130	
Although there is no evidence of a similar fracture pattern in other patients with biallelic 131	
COL1A2 mutations, this finding may reflect atypical bone brittleness due to a complete lack 132	
of normal type I collagen. Considering that type I collagen is the most abundant component 133	
in bone and cartilage, it is likely that complete depletion of the wild-type protein causes a 134	
severe skeletal phenotype with a fracture pattern that differs from the common autosomal 135	
dominant type I collagen-related OI. On the other hand, despite the autosomal recessive 136	
inheritance pattern, these clinical features were in line with type I collagen-related OI 137	
rather than the several autosomal recessive forms of OI [13]. 138	
In contrast to the mutation carriers described by De Paepe et al. who had mild skeletal 139	
manifestations, the mutation carriers reported here lack signs and symptoms of skeletal 140	
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fragility or other OI manifestations [4]. One of them (the mother) has osteopenia but other 141	
carriers have normal BMD and all have a negative fracture history. It is surprising that a 142	
heterozygous glycine substitution within the triple-helical region does not result in any 143	
impaired skeletal phenotype [1, 3, 5, 6]. This suggests that the severity of the OI phenotype 144	
depends on location of the glycine substitution within the helical region. In fact, other 145	
patients with a glycine to serine substitutions in the α2(I) chain have been described as 146	
having mild to moderate OI [4, 12]. However, the mutation we identified locates closer to 147	
the N-terminal α2(I) chain than the other reported cases. In fact, it affects glycine 202 and 148	
mutations in the first 200 N-terminal amino acids only slightly influence the triple helix 149	
stability [1, 14]. This could explain why our carriers do not show any OI manifestation. 150	
Furthermore, it is possible that a more detailed bone tissue assessment with histology and 151	
histomorphometry could have detected mild abnormalities in the heterozygotes, but in any 152	
case there are no clinically obvious manifestations of OI. 153	
In summary, we diagnosed a challenging case of a patient with autosomal recessive OI due 154	
to a novel homozygous COL1A2 mutation, NM_000089.3:c.604G>A, p.(Gly202Ser). 155	
Interestingly, this mutation leads to OI features only in homozygosity. Our finding 156	
underscores the complexity of OI and the variability in its genetic causes and inheritance 157	
pattern. Further, our study emphasizes the importance of a genetic diagnosis in all patients 158	
with OI to ensure correct genetic counselling. 159	
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Table 1. Clinical features of the family members; the index patient and her affected sister 227	
are marked with red text. M= male; F= female; NA= not available; += present; -= absent 228	
 229	
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father 
(I-1) 
68 M 172 100 0 0 -1.0 (T-score) - - - hypertension 
mother 
(I-2) 
59 F 158 90 0 0 -2.1 (T-score) - - - type 2 diabetes, 
arterial hypertension 
index 
(II-4) 
 
31  F 154 48 >10 3 -2.2 (Z-score) + - + - 
sibling1 
(II-1) 
42 F 157 58 0 0 -0.2 (Z-score) - - - - 
sibling 2 
(II-2) 
41 F 163 98 0 0 1.2 (Z-score) - - - Graves’ disease 
sibling 3 
(II-3) 
38 F 155 80 >4 NA -1.3 (Z-score) + + - - 
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Figure legends 232	
 233	
Figure 1 234	
Lateral radiograph of the thoracolumbar spine showing A) A mild biconcave deformity of L1 235	
vertebra. The vertebral fractures sustained during childhood are not clearly evident in the 236	
X-ray and VFA, probably due to vertebral body reshaping during growth. B) Internal fixation 237	
of the pelvis. C) VFA of the same patient; mild biconcave deformity of L1 vertebra. D) 238	
Anteroposterior radiograph of the pelvis showing internal fixation of a right acetabular 239	
fracture. 240	
  241	
Figure 2 242	
A) Pedigree of the family. B) Screenshot from the Integrative Genomic Visualization (IGV) 243	
program showing the WGS reads mapped to reference genome GRCh37 at the COL1A2 244	
locus where the c.604G>A, p.(Gly202Ser) mutation locates. Roman numerals refer to the 245	
pedigree in Fig. 2A. C) Sanger sequencing validation. Arrows indicate the mutation. 246	
  247	
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